- Home
- COYA vs NRXP Comparison
COYA vs NRXP Comparison
Compare COYA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | NRXP |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.8M | 99.2M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | COYA | NRXP |
|---|---|---|
| Price | $4.45 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.80 | ★ $38.25 |
| AVG Volume (30 Days) | 165.4K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | $763.10 | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $1.65 |
| 52 Week High | $7.75 | $5.06 |
Technical Indicators
Market Signals| Indicator | COYA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 55.40 |
| Support Level | $4.50 | $1.83 |
| Resistance Level | $5.18 | $5.06 |
| Average True Range (ATR) | 0.32 | 0.46 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 28.24 | 47.66 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.